Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,896 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04736199 | Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer(ARANOTE) | completed | Phase 3 | 669 | BayerINDUSTRY | 15 | Sep 29, 2026 | clinicaltrials |
| NCT06011304 | Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer | completed | Phase 3 | 287 | HTA Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06754085 | Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer | completed | Phase 3 | 131 | HTA Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06837896 | Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer | completed | Phase 3 | 111 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT00433706 | Image Guided Radiation Therapy For Prostate Cancer | completed | Phase 3 | 470 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06490328 | Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer | completed | Phase 3 | 161 | Dongkook Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT03274687 | Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer | completed | Phase 3 | 296 | NRG OncologyOTHER | 3 | Jul 9, 2026 | clinicaltrials |
| NCT00942331 | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | completed | Phase 3 | 506 | National Cancer Institute (NCI)NIH | 2 | Jun 24, 2026 | clinicaltrials |
| NCT05605964 | Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate | completed | Phase 3 | 387 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT02883049 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations | completed | Phase 3 | 5,949 | National Cancer Institute (NCI)NIH | 7 | Jun 2, 2026 | clinicaltrials |
| NCT02044354 | Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer(CABA-DOC) | completed | Phase 3 | 195 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT00936390 | Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer | completed | Phase 3 | 1,538 | Radiation Therapy Oncology GroupNETWORK | 2 | Mar 6, 2026 | clinicaltrials |
| NCT01546987 | Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer | completed | Phase 3 | 239 | Radiation Therapy Oncology GroupNETWORK | 2 | Mar 6, 2026 | clinicaltrials |
| NCT00063882 | Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 3 | 588 | Radiation Therapy Oncology GroupNETWORK | 2 | Mar 5, 2026 | clinicaltrials |
| NCT06235099 | Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer(Solar-Recur) | completed | Phase 3 | 235 | Curium US LLCINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07413120 | Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery | completed | Phase 3 | 40 | Incheon St.Mary's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT02003924 | Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer(PROSPER) | completed | Phase 3 | 1,401 | PfizerINDUSTRY | 32 | Jan 27, 2026 | clinicaltrials |
| NCT01809691 | S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer(S1216) | completed | Phase 3 | 1,313 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 31, 2025 | clinicaltrials |
| NCT00117286 | Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer | completed | Phase 2 / Phase 3 | 57 | Ferring PharmaceuticalsINDUSTRY | 2 | Dec 18, 2025 | clinicaltrials |
| NCT03009981 | A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer | completed | Phase 3 | 504 | Alliance Foundation Trials, LLC.OTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT02294461 | An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants | completed | Phase 3 | 395 | Astellas Pharma IncINDUSTRY | 4 | Oct 24, 2025 | clinicaltrials |
| NCT04838613 | Study of Diagnostic Performance of [18F]CTT1057 in BCR(GuidePath) | completed | Phase 3 | 190 | Novartis PharmaceuticalsINDUSTRY | 4 | Oct 20, 2025 | clinicaltrials |
| NCT04838626 | Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection(GuideView) | completed | Phase 2 / Phase 3 | 195 | Novartis PharmaceuticalsINDUSTRY | 5 | Oct 7, 2025 | clinicaltrials |
| NCT04186845 | Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence | completed | Phase 3 | 391 | Blue Earth DiagnosticsINDUSTRY | 3 | Sep 22, 2025 | clinicaltrials |
| NCT05590793 | Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate | completed | Phase 3 | 195 | IpsenINDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04534075 | Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial(FIDURA) | completed | Phase 3 | 354 | Sahlgrenska University HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05137561 | Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed Cognitive Fusion TRUS Guided Prostate Biopsy (PROBIOP)(PROBIOP) | completed | Phase 2 / Phase 3 | 217 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT02975934 | A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency(TRITON3) | completed | Phase 3 | 405 | pharmaand GmbHINDUSTRY | 12 | Jul 25, 2025 | clinicaltrials |
| NCT05458856 | Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate(TriptoSwitch) | completed | Phase 3 | 147 | IpsenINDUSTRY | 7 | Jul 25, 2025 | clinicaltrials |
| NCT03834506 | Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) | completed | Phase 3 | 1,030 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Jul 18, 2025 | clinicaltrials |
| NCT05547386 | 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 3 | 163 | Mayo ClinicOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04742361 | Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer | completed | Phase 3 | 136 | ABX advanced biochemical compounds GmbHINDUSTRY | 3 | Jul 15, 2025 | clinicaltrials |
| NCT04100018 | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer(CheckMate 7DX) | completed | Phase 3 | 1,030 | Bristol-Myers SquibbINDUSTRY | 28 | Jun 12, 2025 | clinicaltrials |
| NCT03072238 | Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer(IPATential150) | completed | Phase 3 | 1,101 | Hoffmann-La RocheINDUSTRY | 26 | Jun 6, 2025 | clinicaltrials |
| NCT00667069 | Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer | completed | Phase 3 | 424 | UNICANCEROTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06984159 | The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart. | completed | Phase 3 | 137 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 22, 2025 | clinicaltrials |
| NCT03834519 | Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)(KEYLYNK-010) | completed | Phase 3 | 793 | Merck Sharp & Dohme LLCINDUSTRY | 20 | May 18, 2025 | clinicaltrials |
| NCT03822845 | Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer | completed | Phase 2 / Phase 3 | 6 | Michael Graham PhD, MDOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT03936218 | Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer | completed | Phase 3 | 94 | Eurofarma Laboratorios S.A.INDUSTRY | 1 | Apr 17, 2025 | clinicaltrials |
| NCT01220869 | A Study of Degarelix in Taiwanese Patients With Prostate Cancer | completed | Phase 3 | 110 | Ferring PharmaceuticalsINDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT02288247 | A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone(PRESIDE) | completed | Phase 3 | 688 | Astellas Pharma Europe Ltd.INDUSTRY | 16 | Apr 8, 2025 | clinicaltrials |
| NCT04186819 | Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer. | completed | Phase 3 | 356 | Blue Earth DiagnosticsINDUSTRY | 4 | Feb 26, 2025 | clinicaltrials |
| NCT00104676 | Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors | completed | Phase 3 | 263 | UNICANCEROTHER | 3 | Feb 6, 2025 | clinicaltrials |
| NCT00887198 | Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 3 | 1,088 | Janssen Research & Development, LLCINDUSTRY | 11 | Feb 4, 2025 | clinicaltrials |
| NCT01715285 | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | completed | Phase 3 | 1,209 | Janssen Research & Development, LLCINDUSTRY | 33 | Feb 4, 2025 | clinicaltrials |
| NCT03103321 | Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer | completed | Phase 3 | 158 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT03511664 | Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer(VISION) | completed | Phase 3 | 861 | EndocyteINDUSTRY | 10 | Jan 13, 2025 | clinicaltrials |
| NCT02220829 | Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy | completed | Phase 3 | 148 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01726374 | Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours(111) | completed | Phase 3 | 246 | Institute of Cancer Research, United KingdomOTHER | 1 | Dec 4, 2024 | clinicaltrials |
Data updated 23 hours agoSource updated Sep 29, 2026source: clinicaltrials